BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Sylwia WasiakKim E DzoboBrooke D RakaiYannick KaiserMiranda VerslootMahnoush BahjatStephanie C StotzLi FuMichael SweeneyJan O JohanssonNorman C W WongErik S G StroesJeffrey KroonEwelina KulikowskiPublished in: Clinical epigenetics (2020)
Monocytes isolated from DM2 + CVD patients receiving standard of care therapies are in a hyper-inflammatory state and hyperactive upon IFNγ stimulation. Apabetalone treatment diminishes this pro-inflammatory phenotype, providing mechanistic insight into how BET protein inhibition may reduce CVD risk in DM2 patients.
Keyphrases
- type diabetes
- cardiovascular disease
- end stage renal disease
- dendritic cells
- glycemic control
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- protein protein
- prognostic factors
- amino acid
- peripheral blood
- oxidative stress
- palliative care
- peritoneal dialysis
- binding protein
- quality improvement
- insulin resistance
- coronary artery disease
- combination therapy
- patient reported outcomes
- cardiovascular events
- skeletal muscle
- affordable care act